Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Avita Medical ( (RCEL) ) just unveiled an announcement.
On January 13, 2026, AVITA Medical reported unaudited preliminary results showing full-year 2025 revenue of approximately $71.6 million, up about 11% from 2024 and within its revised guidance, despite a slight year-on-year decline in fourth-quarter revenue to roughly $17.6 million. The company refinanced its existing debt on the same date by closing a new five-year senior secured credit facility of up to $60 million with Perceptive Advisors, immediately drawing $50 million to repay prior borrowings and bolster liquidity, with an additional $10 million available through the first quarter of 2027. The new facility, secured against substantially all company assets and guaranteed by a U.S. subsidiary, introduces revenue-based financial covenants and minimum cash requirements that tighten operational discipline while resetting covenant levels to align with current performance. In conjunction with the financing, AVITA agreed to issue a 10-year warrant to Perceptive Advisors for up to 500,000 shares of common stock, potentially rising to 650,000 shares if the additional $10 million is drawn, subject to shareholder approval under Australian listing rules. Management highlighted that the strengthened balance sheet, together with advancing clinical programs—including full enrollment of the Cohealyx-I study and over 75% enrollment in PermeaDerm-I as of December 2025—positions the company to shift from stabilization to execution-led growth in 2026, when it expects to deliver revenue of approximately $80 million to $85 million, implying a 12% to 19% increase over 2025.
The most recent analyst rating on (RCEL) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Avita Medical stock, see the RCEL Stock Forecast page.
Spark’s Take on RCEL Stock
According to Spark, TipRanks’ AI Analyst, RCEL is a Neutral.
The score is held down primarily by weak financial performance (large losses, negative cash flow, and negative equity). Technicals are also soft with bearish longer-term trend signals. These negatives are partially offset by improving reimbursement visibility and disciplined cost actions from the latest earnings call, plus a modestly positive leadership update.
To see Spark’s full report on RCEL stock, click here.
More about Avita Medical
AVITA Medical, Inc. is a therapeutic acute wound care company that develops and markets transformative solutions designed to optimize wound healing and accelerate patient recovery. Its flagship RECELL System, approved by the U.S. Food and Drug Administration for thermal burn and trauma wounds, creates Spray-On Skin Cells from a patient’s own skin, and the company also holds U.S. manufacturing and exclusive marketing rights for PermeaDerm, a biosynthetic wound matrix, and Cohealyx, a collagen-based dermal matrix, with additional RECELL approvals across Europe, Australia (excluding RECELL GO), and Japan for a range of skin-healing applications.
Average Trading Volume: 228,600
Technical Sentiment Signal: Sell
Current Market Cap: $103.7M
For detailed information about RCEL stock, go to TipRanks’ Stock Analysis page.